TOday’s Movers: Johnson & Johnson (NYSE:JNJ) Stock Rating Reiterated by Jefferies & Co; $140.00 Target Price Indicates 4.21 % Potential

June 19, 2017 - By Darrin Black

 TOday’s Movers: Johnson & Johnson (NYSE:JNJ) Stock Rating Reiterated by Jefferies & Co; $140.00 Target Price Indicates 4.21 % Potential

Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.12, from 0.82 in 2016Q3. It is positive, as 63 investors sold Johnson & Johnson shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported.

Rwc Asset Mngmt Limited Liability Partnership holds 4.05% or 538,766 shares in its portfolio. 39,139 are held by Segment Wealth Management Ltd Liability Corporation. Flossbach Von Storch Ag reported 1.53 million shares. Pennsylvania-based Orrstown Financial has invested 1.49% in Johnson & Johnson (NYSE:JNJ). Bridges Inv Counsel invested in 74,121 shares or 2.08% of the stock. Mathes Communications Inc accumulated 35,707 shares or 2.27% of the stock. Prentiss Smith Commerce owns 73,981 shares. Culbertson A N & holds 2.85% or 72,760 shares. Concannon Wealth Mngmt Lc reported 2,520 shares stake. Investment House Limited Liability Corp invested in 108,953 shares. Burt Wealth Advisors invested 1.28% of its portfolio in Johnson & Johnson (NYSE:JNJ). Macguire Cheswick & Tuttle Invest Counsel Lc holds 3.24% or 136,349 shares in its portfolio. Delta Lloyd Nv holds 1.99% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 551,170 shares. Joel Isaacson And Limited Liability, a New York-based fund reported 44,012 shares. Rothschild Partners reported 2,286 shares.

Since February 1, 2017, it had 0 insider purchases, and 5 insider sales for $14.98 million activity. Shares for $1.99 million were sold by Pruden Gary J. $2.45M worth of Johnson & Johnson (NYSE:JNJ) was sold by Ullmann Michael H. Kapusta Ronald A also sold $1.78M worth of Johnson & Johnson (NYSE:JNJ) shares. The insider Stoffels Paulus sold $2.58 million. $6.18 million worth of stock was sold by Duato Joaquin on Friday, March 3.

Johnson & Johnson (NYSE:JNJ) Rating Reaffirmed

The firm has just set a target price per share of $140.00 on Johnson & Johnson (NYSE:JNJ) shares. This is 4.21 % from the last stock price. In analysts note issued to clients and investors on 16 June, Jefferies & Co reaffirmed their Hold rating on shares of JNJ.

Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.12, from 0.82 in 2016Q3. It is positive, as 63 investors sold Johnson & Johnson shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported.

Rwc Asset Mngmt Limited Liability Partnership holds 4.05% or 538,766 shares in its portfolio. 39,139 are held by Segment Wealth Management Ltd Liability Corporation. Flossbach Von Storch Ag reported 1.53 million shares. Pennsylvania-based Orrstown Financial has invested 1.49% in Johnson & Johnson (NYSE:JNJ). Bridges Inv Counsel invested in 74,121 shares or 2.08% of the stock. Mathes Communications Inc accumulated 35,707 shares or 2.27% of the stock. Prentiss Smith Commerce owns 73,981 shares. Culbertson A N & holds 2.85% or 72,760 shares. Concannon Wealth Mngmt Lc reported 2,520 shares stake. Investment House Limited Liability Corp invested in 108,953 shares. Burt Wealth Advisors invested 1.28% of its portfolio in Johnson & Johnson (NYSE:JNJ). Macguire Cheswick & Tuttle Invest Counsel Lc holds 3.24% or 136,349 shares in its portfolio. Delta Lloyd Nv holds 1.99% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 551,170 shares. Joel Isaacson And Limited Liability, a New York-based fund reported 44,012 shares. Rothschild Partners reported 2,286 shares.

Since February 1, 2017, it had 0 insider purchases, and 5 insider sales for $14.98 million activity. Shares for $1.99 million were sold by Pruden Gary J. $2.45M worth of Johnson & Johnson (NYSE:JNJ) was sold by Ullmann Michael H. Kapusta Ronald A also sold $1.78M worth of Johnson & Johnson (NYSE:JNJ) shares. The insider Stoffels Paulus sold $2.58 million. $6.18 million worth of stock was sold by Duato Joaquin on Friday, March 3.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 16 analysts covering Johnson & Johnson (NYSE:JNJ), 8 have Buy rating, 1 Sell and 7 Hold. Therefore 50% are positive. Johnson & Johnson has $145 highest and $90 lowest target. $119.10’s average target is -11.26% below currents $134.21 stock price. Johnson & Johnson had 44 analyst reports since August 7, 2015 according to SRatingsIntel. Societe Generale initiated Johnson & Johnson (NYSE:JNJ) on Wednesday, April 6 with “Hold” rating. The firm has “Neutral” rating by Atlantic Securities given on Friday, December 18. The stock has “Market Perform” rating by Wells Fargo on Thursday, January 26. On Thursday, July 14 the stock rating was maintained by Jefferies with “Hold”. The stock of Johnson & Johnson (NYSE:JNJ) has “Outperform” rating given on Wednesday, October 7 by RBC Capital Markets. The stock of Johnson & Johnson (NYSE:JNJ) has “Hold” rating given on Tuesday, June 14 by Jefferies. On Wednesday, October 14 the stock rating was maintained by S&P Research with “Buy”. The stock of Johnson & Johnson (NYSE:JNJ) has “Neutral” rating given on Monday, March 14 by Goldman Sachs. UBS initiated the stock with “Buy” rating in Tuesday, September 22 report. The company was maintained on Wednesday, July 20 by RBC Capital Markets.

About 731 shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since June 19, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on July, 18. They expect $1.78 earnings per share, up 2.30 % or $0.04 from last year’s $1.74 per share. JNJ’s profit will be $4.84B for 18.84 P/E if the $1.78 EPS becomes a reality. After $1.83 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -2.73 % negative EPS growth.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company has market cap of $365.10 billion. It operates through three divisions: Consumer, Pharmaceutical and Medical Devices. It has a 22.56 P/E ratio. The Company’s primary focus is products related to human health and well-being.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Reuters.com which released: “Johnson & Johnson’s flu drug succeeds in mid-stage trial” on June 14, 2017, also Seekingalpha.com with their article: “Johnson & Johnson’s (JNJ) Management Presents at Goldman Sachs 38th Annual …” published on June 15, 2017, Prnewswire.com published: “Johnson & Johnson Announces Completion of Acquisition of Actelion” on June 16, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Fiercebiotech.com and their article: “Idorsia spins out of Johnson & Johnson-Actelion with $1B and multidrug …” published on June 16, 2017 as well as Fiercebiotech.com‘s news article titled: “Johnson & Johnson unveils new obesity, arthritis collaborations, shares its …” with publication date: June 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.